# Wave reports dosing under way in the multidose Phase 2a part of WVE-007's INLIGHT trial

Canonical page: https://technooptimist.io/stories/wave-reports-dosing-under-way-in-the-multidose-phase-2a-part-of-wve-007-a8035595
Date: 30 Jul 2026
About: [Wave Life Sciences](https://technooptimist.io/companies/wave-life-sciences.md) · [WVE-007](https://technooptimist.io/biotech/wve-007.md)
Original source: https://www.globenewswire.com/news-release/2026/07/30/3335935/0/en/wave-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business-update.html

In its second-quarter 2026 update, Wave said dosing has started in the multidose Phase 2a portion of the INLIGHT trial of WVE-007. The portion enrolls adults with higher body weight, with and without type 2 diabetes, in the US and Europe, and follows them for 12 months. The company also said more INLIGHT data, including from the 600 mg single-dose cohort, are expected in the second half of 2026.

## Key facts

- Participants are assessed for body weight, waist size, body composition, liver fat, HbA1c and lipids over 12 months.
- The release gives no dose levels, dosing schedule or number of doses for the multidose portion.
- Wave expects to start Phase 2 trials of WVE-007 in combination and maintenance settings in the second half of 2026.
- An investor day with pipeline updates is planned for fall 2026.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.